Mr. Chair, this was an issue that Health Canada examined a number of years ago. The government early in its tenure took a decision not to proceed with regulations to require tamper-resistant formulations.
I want to be clear that certainly Health Canada encourages companies to come forward if they wish to market tamper-resistant formulations, but there is research indicating that you have what's called the “balloon effect”, which is that if we were to force a particular class of medications to require tamper resistance, you'd see people migrate to other drugs that were not tamper-resistant. There's a real research issue as to whether that's an effective strategy for countering the opioid crisis.